BlueprintJPM2025BPMCslidesvF

Blueprint MedicinesDriving growth and innovation with operational excellenceKate Haviland, Chief Executive OfficerJ.P. Morgan Healthcare ConferenceJanuary 13, 2025Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for the company’s operations, including its growth strategies, opportunities and expectations for 2025 and beyond; the company’s expectations regarding its estimated peak revenue for AYVAKIT and the systemic mastocytosis market; continued growth in the breadth and depth of prescribing for AYVAKIT; the company’s development plans and expectations regarding BLU-808, including its potential treatment for mast cell disorders, as well as other potential related allergic-inflammatory indications; expectations related to the markets for the company’s current or future app